Anti-Mouse CD279 (PD-1) – DyLight® 650

Pricing & Details

Product No.P359
Clone
J43
Protein
PD-1
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
programmed death-1, CD279
Isotype
Armenian Hamster
IgG
Applications
FC
,
ICC
Prod No.
Size
Price
Avail.
Qty
Add to cart
P359-50 µg
50 µg
$85.00
In stock
Max:
Min: 1
Step: 1
P359-100 µg
100 µg
$150.00
In stock
Max:
Min: 1
Step: 1
P359-200 µg
200 µg
$250.00
In stock
Max:
Min: 1
Step: 1

Antibody Details

Product Details

Reactivity Species
Mouse
Host Species
Armenian Hamster
Immunogen
Purified Recombinant Mouse PD-1 (>98%)
Product Concentration
0.2 mg/ml
Formulation
This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Excitation Laser
Red Laser (652 nm)
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone J43 recognizes an epitope on mouse PD-1.
Antigen Distribution
PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.
Background
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.

Antigen Details

Protein
Ligand/Receptor
B7-H1 (PD-L1) and B7-DC (PD-L2)
PubMed
NCBI Gene Bank ID
Research Area
Cancer
.
Immunology
.
Innate Immunity
Flow Cytometry

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Cookie Policy
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy.